These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

887 related articles for article (PubMed ID: 24112608)

  • 21. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
    Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
    Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
    Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
    Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
    J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
    Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
    Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
    Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
    Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.
    Sungwan P; Panaampon J; Kariya R; Kamio S; Nakagawa R; Hirozane T; Ogura Y; Abe M; Hirabayashi K; Fujiwara Y; Kikuta K; Okada S
    Hum Cell; 2024 Jul; 37(4):1215-1225. PubMed ID: 38755432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
    Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
    Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
    Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
    Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
    Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
    Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL
    Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.